453 Results

People

  1. Kelsen
    Kelsen
  2. Motzer
    Motzer
  3. Kris
    Kris
  4. Saltz
    Saltz
  5. Abrey
    Abrey
  6. O'Reilly
    O'Reilly
  7. Schwartz
    Schwartz
  8. Hudis
    Hudis
  9. Aghajanian
    Aghajanian
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (312)
  2. Solid Tumor Oncology Division (250)
  3. Survivorship Research (79)
  4. Gastrointestinal Oncology Service (76)
  5. Hematologic Malignancies, Division of (76)
  6. Radiology, Department of (64)
  7. Center for Hematologic Malignancies (63)
  8. Epidemiology and Biostatistics (61)
  9. Biostatistics Service (60)
  10. Genitourinary Oncology Service (59)
  1. "leukopenia"
Formats
  1. Journal Article (435)
  2. Review (9)
  3. Conference Paper (4)
  4. Editorial (2)
  5. Research Letter (2)
  6. Miscellaneous (1)
Groups
  1. Department of Medicine (312)
  2. Solid Tumor Oncology Division (250)
  3. Survivorship Research (79)
  4. Gastrointestinal Oncology Service (76)
  5. Hematologic Malignancies, Division of (76)
  6. Radiology, Department of (64)

More Groups

People
  1. David Kelsen (33)
  2. Robert Motzer (29)
  3. Mark Kris (25)
  4. Leonard Saltz (21)
  5. Eileen O'Reilly (18)
  6. Lauren Abrey (18)

More People

Years
  1. 2025 (10)
  2. 2024 (26)
  3. 2023 (9)
  4. 2022 (8)
  5. 2021 (6)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (42)
  2. Cancer (33)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (15)
  5. Gynecologic Oncology (14)
  6. Investigational New Drugs (14)

More Publications

Publishers
  1. Elsevier Inc. (68)
  2. Springer (52)
  3. American Society of Clinical Oncology (43)
  4. Wiley Blackwell (39)
  5. American Association for Cancer Research (36)
  6. Oxford University Press (33)

More Publishers

Results (453)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • 90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
    Journal Article

    Picozzi, V. J.; Ramanathan, R. K.; Lowery, M. A.; Ocean, A. J.; Mitchel, E. P.; O'Neil, B. H.; Guarino, M. J.; Conkling, P. R.; Cohen, S. J.; Bahary, N.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
    Journal Article

    Hussain, M.; Rathkopf, D.; Liu, G.; Armstrong, A.; Kelly, W. K.; Ferrari, A.; Hainsworth, J.; Joshi, A.; Hozak, R. R.; Yang, L.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
    Journal Article

    Coleman, R. L.; Sill, M. W.; Bell-Mcguinn, K.; Aghajanian, C.; Gray, H. J.; Tewari, K. S.; Rubin, S. C.; Rutherford, T. J.; Chan, J. K.; Chen, A.; more...
    Gynecologic Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group
    Journal Article

    Burke, M. J.; Ahern, C.; Weigel, B. J.; Poirier, J. T.; Rudin, C. M.; Chen, Y.; Cripe, T. P.; Bernhardt, M. B.; Blaney, S. M.
    Pediatric Blood and Cancer (2015)

    Fulltext@MSK | Save
  • A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors
    Journal Article

    Diaz, L. A. Jr; Coughlin, C. M.; Weil, S. C.; Fishel, J.; Gounder, M. M.; Lawrence, S.; Azad, N.; O'Shannessy, D. J.; Grasso, L.; Wustner, J.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Maitake mushroom extract in myelodysplastic syndromes (MDS): A phase II study
    Journal Article

    Wesa, K. M.; Cunningham Rundles, S.; Klimek, V. M.; Vertosick, E.; Coleton, M. I.; Yeung, K. S.; Lin, H.; Nimer, S.; Cassileth, B. R.
    Cancer Immunology, Immunotherapy (2015)

    Fulltext@MSK | Save
  • Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
    Journal Article

    Straus, D. J.; Hamlin, P. A.; Matasar, M. J.; Lia Palomba, M.; Drullinsky, P. R.; Zelenetz, A. D.; Gerecitano, J. F.; Noy, A.; Hamilton, A. M.; Elstrom, R.; more...
    British Journal of Haematology (2015)

    Fulltext@MSK | Save
  • Infection risk in breast cancer patients treated with trastuzumab: A systematic review and meta-analysis
    Journal Article

    Funakoshi, T.; Suzuki, M.; Muss, H. B.
    Breast Cancer Research and Treatment (2015)

    Fulltext@MSK | Save
  • Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)
    Journal Article

    Sikov, W. M.; Berry, D. A.; Perou, C. M.; Singh, B.; Cirrincione, C. T.; Tolaney, S. M.; Kuzma, C. S.; Pluard, T. J.; Somlo, G.; Port, E. R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save